Literature DB >> 446055

Tetanus: a review.

D D Alfery, L A Rauscher.   

Abstract

Tetanus is caused by the organism Clostridium tetani, which produces tetanospasmin, a neurotoxin responsible for the clinical manifestations of muscle rigidity and reflex spasms. The majority of cases follow an anaerobic wound infection associated with trauma. Incubation period is usually 3 days to 3 weeks. 75% of patients present with trismus. Reflex spasms are seen in 70% of patients and characterize the severity of the disease. Treatment involves removal of the offending organism, neutralization of free neurotoxin, controlling rigidity and reflex spasm, and minimizing complications. Diazepam may be used alone in mild cases. Severe cases require the addition of nondepolarizing neuromuscular blocking agents and mechanical ventilation. Respiratory complications occur early and require aggressive airway management. A serious, late complication is the syndrome of sympathetic nervous system overactivity that is treated with alpha and beta blockade. High mortality rates seen in the United States may be due to delays in diagnosis and lack of familiarity with treatment. The disease is preventable with adequate immunization.

Entities:  

Mesh:

Year:  1979        PMID: 446055     DOI: 10.1097/00003246-197904000-00007

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

1.  Sedation by propofol in tetanus--is it a muscular relaxant?

Authors:  A Borgeat; C Dessibourg; M Rochani; P M Suter
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

2.  The use of magnesium sulphate infusions in the management of very severe tetanus.

Authors:  M F James; E D Manson
Journal:  Intensive Care Med       Date:  1985       Impact factor: 17.440

3.  Elimination of maternal and neonatal tetanus: a 21st-century challenge.

Authors:  Sharon Owusu-Darko; Khady Diouf; Nawal M Nour
Journal:  Rev Obstet Gynecol       Date:  2012

4.  Metabolic changes in patients severely affected by tetanus.

Authors:  A Hiraide; M Katayama; H Sugimoto; T Yoshioka; T Sugimoto
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

5.  Treatment of severe tetanus by intrathecal injections of baclofen without artificial ventilation.

Authors:  J M Saissy; J Demazière; M Vitris; M Seck; L Marcoux; M Gaye; M Ndiaye
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

6.  Molecular and evolutionary analysis of NEAr-iron Transporter (NEAT) domains.

Authors:  Erin S Honsa; Anthony W Maresso; Sarah K Highlander
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

7.  Patients with severe accidental tetanus admitted to an intensive care unit in Northeastern Brazil: clinical-epidemiological profile and risk factors for mortality.

Authors:  Marcus Vinícius Dantas da Nóbrega; Ricardo Coelho Reis; Isabel Cristina Veras Aguiar; Timóteo Vasconcelos Queiroz; Ana Claudia Feitosa Lima; Eanes Delgado Barros Pereira; Raquel Feijó de Araújo Ferreira
Journal:  Braz J Infect Dis       Date:  2016-07-29       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.